TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET CHALLENGE MATRIX
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR VENDOR SHARE ANALYSIS
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING NUMBER OF CHRONIC DISEASES
3.1.2 RISING AGING POPULATION
3.1.3 GROWING NUMBER OF DIAGNOSTIC CENTERS
3.1.4 INCREASE IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES OF CONTRAST AGENTS
3.2 RESTRAINT
3.2.1 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS
3.3 OPPORTUNITIES
3.3.1 RISING HEALTHCARE EXPENDITURE
3.3.2 INCREASE IN NUMBER OF PUBLIC AND PRIVATE HOSPITALS
3.4 CHALLENGE
3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 KEY PRIMARY INSIGHTS
7 EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE
7.1 OVERVIEW
7.2 IODINATED CONTRAST MEDIA
7.3 BARIUM-BASED CONTRAST MEDIA
7.4 MICROBUBBLE CONTRAST MEDIA
7.5 GOLD NANOPARTICLE CONTRAST AGENTS
7.6 OTHERS
8 EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CARDIOLOGY
8.2.1 PERCUTANEOUS CORONARY INTERVENTION
8.2.2 STRUCTURAL HEART DISEASE
8.2.3 CONGENITAL HEART DISEASE
8.2.4 ELECTROPHYSIOLOGY
8.3 GASTROENTEROLOGY
8.4 NEUROLOGY
8.5 ONCOLOGY
8.6 UROLOGY
8.7 GENERAL SURGERY
9 EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER
9.1 OVERVIEW
9.2 IMAGING CENTERS
9.3 HOSPITAL
9.4 CLINICS
9.5 DIAGNOSTIC CENTER
9.6 AMBULATORY SURGICAL CENTERS
9.7 PRIVATE PRACTICES
10 EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY
10.1 EUROPE
10.1.1 GERMANY
10.1.2 U.K.
10.1.3 FRANCE
10.1.4 ITALY
10.1.5 SPAIN
10.1.6 SWITZERLAND
10.1.7 NETHERLANDS
10.1.8 RUSSIA
10.1.9 BELGIUM
10.1.10 TURKEY
10.1.11 REST OF EUROPE
11 EUROPE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS; EUROPE
12 COMPANY PROFILES
12.1 BRACCO
12.1.1 COMPANY SNAPSHOT
12.1.2 GEOGRAPHICAL PRESENCE
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 PRODUCT PORTFOLIO
12.1.5 RECENT DEVELOPMENTS
12.2 GENERAL ELECTRIC COMPANY
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENEUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 PRODUCT PORTFOLIO
12.2.5 RECENT DEVELOPMENTS
12.3 GUERBET
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENEUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 PRODUCT PORTFOLIO
12.3.5 RECENT DEVELOPMENTS
?
12.4 FUJIFILM VISUALSONICS INC.
12.4.1 COMPANY SNAPSHOT
12.4.2 GEOGRAPHICAL PRESENCE
12.4.3 PRODUCT PORTFOLIO
12.4.4 RECENT DEVELOPMENT
12.5 IMAX
12.5.1 COMPANY SNAPSHOT
12.5.2 GEOGRAPHICAL PRESENCE
12.5.3 PRODUCT PORTFOLIO
12.5.4 RECENT DEVELOPMENT
12.6 J.B. CHEMICALS & PHARMACEUTICALS LTD.
12.6.1 COMPANY SNAPSHOT
12.6.2 REVENUE ANALYSIS
12.6.3 PRODUCT PORTFOLIO
12.6.4 RECENT DEVELOPMENT
12.7 JODAS EXPOIM
12.7.1 COMPANY SNAPSHOT
12.7.2 GEOGRAPHICAL PRESENCE
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8 LANTHEUS MEDICAL IMAGING, INC.
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 NANO THERAPEUTICS PVT. LTD.
12.9.1 COMPANY SNAPSHOT
12.9.2 GEOGRAPHICAL PRESENCE
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.10 NOVALEK PHARMACEUTICALS PVT. LTD.
12.10.1 COMPANY SNAPSHOT
12.10.2 GEOGRAPHICAL PRESENCE
12.10.3 PRODUCT PORTFOLIO
12.10.4 RECENT DEVELOPMENT
12.11 TAEJOON PHARM
12.11.1 COMPANY SNAPSHOT
12.11.2 GEOGRAPHICAL PRESENCE
12.11.3 PRODUCT PORTFOLIO
12.11.4 RECENT DEVELOPMENT
12.12 UNIJULES LIFE SCIENCES LTD.
12.12.1 COMPANY SNAPSHOT
12.12.2 PRODUCT PORTFOLIO
12.12.3 RECENT DEVELOPMENT
13 QUESTIONNAIRE
14 RELATED REPORTS